119 related articles for article (PubMed ID: 8128627)
1. Cellular thymidine kinase activity is required for the inhibition of HIV-1 replication by AZT in lymphocytes.
Lowy I; Caruso M; Goff SP; Klatzmann D
Virology; 1994 Apr; 200(1):271-5. PubMed ID: 8128627
[TBL] [Abstract][Full Text] [Related]
2. Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection.
Avramis VI; Kwock R; Solorzano MM; Gomperts E
J Acquir Immune Defic Syndr (1988); 1993 Dec; 6(12):1287-96. PubMed ID: 8254464
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells.
Törnevik Y; Ullman B; Balzarini J; Wahren B; Eriksson S
Biochem Pharmacol; 1995 Mar; 49(6):829-37. PubMed ID: 7702641
[TBL] [Abstract][Full Text] [Related]
4. AZT-5'-(p-bromophenyl methoxyalaninyl phosphate) as a potent and non-toxic anti-human immunodeficiency virus agent.
Jan ST; Zhu Z; Tai HL; Shih MJ; Venkatachalam TK; Uckun FM
Antivir Chem Chemother; 1999 Jan; 10(1):47-52. PubMed ID: 10079879
[TBL] [Abstract][Full Text] [Related]
5. Thymidine and zidovudine metabolism in chronically zidovudine-exposed cells in vitro.
Agarwal RP; Mian AM
Biochem Pharmacol; 1991 Jul; 42(4):905-11. PubMed ID: 1867645
[TBL] [Abstract][Full Text] [Related]
6. 5'-Hydrogenphosphonates of anti-HIV nucleoside analogues revisited: controversial mode of action.
Gosselin G; Périgaud C; Lefebvre I; Pompon A; Aubertin AM; Kirn A; Szabo T; Stawinski J; Imbach JL
Antiviral Res; 1993 Oct; 22(2-3):143-53. PubMed ID: 8279809
[TBL] [Abstract][Full Text] [Related]
7. In vitro selection of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine.
Dianzani F; Antonelli G; Turriziani O; Dong G; Capobianchi MR; Riva E
Antiviral Res; 1992 May; 18(1):39-52. PubMed ID: 1384427
[TBL] [Abstract][Full Text] [Related]
8. Low-dose, sublingual AZT-monophosphate therapy for HIV+ patients?
Johnson S
Med Hypotheses; 2001 Mar; 56(3):409-10. PubMed ID: 11359372
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.
Rosowsky A; Fu H; Pai N; Mellors J; Richman DD; Hostetler KY
J Med Chem; 1997 Aug; 40(16):2482-90. PubMed ID: 9258355
[TBL] [Abstract][Full Text] [Related]
10. [Genetically controlled pharmacomodulation: application to the treatment of HIV infection].
Caruso M; Klatzmann D
C R Acad Sci III; 1994 Nov; 317(11):1027-30. PubMed ID: 7882139
[TBL] [Abstract][Full Text] [Related]
11. Use of herpes simplex virus thymidine kinase to improve the antiviral activity of zidovudine.
Guettari N; Loubière L; Brisson E; Klatzmann D
Virology; 1997 Sep; 235(2):398-405. PubMed ID: 9281520
[TBL] [Abstract][Full Text] [Related]
12. Zidovudine induces the expression of cellular resistance affecting its antiviral activity.
Dianzani F; Antonelli G; Turriziani O; Riva E; Simeoni E; Signoretti C; Strosselli S; Cianfriglia M
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1471-8. PubMed ID: 7888202
[TBL] [Abstract][Full Text] [Related]
13. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
Gao WY; Johns DG; Tanaka M; Mitsuya H
Mol Pharmacol; 1999 Mar; 55(3):535-40. PubMed ID: 10051538
[TBL] [Abstract][Full Text] [Related]
14. Intracellular metabolism of CycloSaligenyl 3'-azido-2', 3'-dideoxythymidine monophosphate, a prodrug of 3'-azido-2', 3'-dideoxythymidine (zidovudine).
Balzarini J; Naesens L; Aquaro S; Knispel T; Perno C; De Clercq E; Meier C
Mol Pharmacol; 1999 Dec; 56(6):1354-61. PubMed ID: 10570065
[TBL] [Abstract][Full Text] [Related]
15. AZT and AZT-monophosphate prodrugs incorporating HIV-protease substrate fragment: synthesis and evaluation as specific drug delivery systems.
Liotard JF; Mehiri M; Di Giorgio A; Boggetto N; Reboud-Ravaux M; Aubertin AM; Condom R; Patino N
Antivir Chem Chemother; 2006; 17(4):193-213. PubMed ID: 17066898
[TBL] [Abstract][Full Text] [Related]
16. Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.
Kerr SG; Anderson KS
Biochemistry; 1997 Nov; 36(46):14064-70. PubMed ID: 9369478
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HIV-1 replication in macrophages by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and 9-(R)-2-(phosphono methoxypropyl)adenine.
Franchetti P; Rossi L; Cappellacci L; Pasqualini M; Grifantini M; Balestra E; Forbici F; Perno CF; Serafini S; Magnani M
Antivir Chem Chemother; 2001 May; 12(3):151-9. PubMed ID: 12959323
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, anti-HIV activity and stability studies of 3'-azido-2',3'-dideoxythymidine 5'-fluorophosphate.
Egron D; Arzumanov AA; Dyatkina NB; Krayevsky A; Imbach JL; Aubertin AM; Gosselin G; Périgaud C
Nucleosides Nucleotides; 1999; 18(4-5):983-4. PubMed ID: 10432725
[TBL] [Abstract][Full Text] [Related]
19. [Inhibition of reproduction of the human immunodeficiency virus in cell culture by 2',3'-dideoxynucleoside-5'-phosphites].
Karamov EV; Lukashov VV; Gorbacheva AP; Makarova TV; Kornilaeva GV; Tarusova NB; Kraevskiĭ AA
Mol Biol (Mosk); 1992; 26(1):201-7. PubMed ID: 1508170
[TBL] [Abstract][Full Text] [Related]
20. Amino acid phosphoramidate monoesters of 3'-azido-3'-deoxythymidine: relationship between antiviral potency and intracellular metabolism.
Chang S; Griesgraber GW; Southern PJ; Wagner CR
J Med Chem; 2001 Jan; 44(2):223-31. PubMed ID: 11170632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
